Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCVS Caremark Terbinafine Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 364-A

    Initial Prior Authorization Terbinafine Tablets

    Customize your policy alerts

    Sign up for cvs_caremark Policy 364-A alerts

    Get alerted when Policy 364-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial prior authorization coverage for generic terbinafine tablets used to treat onychomycosis, tinea capitis, tinea corporis, and tinea cruris.

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization Terbinafine Tablets
    Policy CodePolicy 364-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor onychomycosis, document confirmation of the diagnosis with a fungal diagnostic test and confirm that terbinafine is not being used in a footbath.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3 monthsDuration of approval
    3Covered indication groups
    1Diagnostic confirmation requirement for onychomycosis

    Coverage Criteria

    Onychomycosis

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered when all of the following are met.

    • Diagnostic confirmation: The patient's diagnosis has been confirmed with a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy).
    • Administration restriction: The requested drug is NOT being used in a footbath.

    Tinea Capitis

    Covered when the following criterion is met.

    Tinea capitis: The requested drug is being prescribed for the treatment of tinea capitis and is NOT being used in a footbath.

    Tinea Corporis or Tinea Cruris

    Covered when all of the following are met.

    Tinea corporis or tinea cruris

    • Qualifying clinical circumstance

      • Extensive disease: The patient has extensive disease.
      • Dermatophyte folliculitis is present.
      • Topical therapy failure: The patient did NOT respond to topical therapy.
      • Immunocompromised status: The patient is immunocompromised.
    • Administration restriction: The requested drug is NOT being used in a footbath.

    Use of terbinafine tablets in a footbath is not authorized for any indication covered by this policy.

    Initial Therapy Criteria

    Onychomycosis

    Authorization may be granted for onychomycosis when all of the following criteria are met.

    Onychomycosis initial therapy

    • Diagnostic confirmation: The patient's diagnosis has been confirmed with a fungal diagnostic test (e.g., potassium hydroxide [KOH] preparation, fungal culture, or nail biopsy).
    • Administration restriction: The requested drug is NOT being used in a footbath.

    Tinea Capitis

    Authorization may be granted for tinea capitis when the following criterion is met.

    Tinea capitis initial therapy: The requested drug is NOT being used in a footbath.

    Tinea Corporis or Tinea Cruris

    Authorization may be granted for tinea corporis or tinea cruris when all of the following criteria are met.

    Tinea corporis or tinea cruris initial therapy

    • Qualifying clinical circumstance

      • Extensive disease: The patient has extensive disease.
      • Dermatophyte folliculitis is present.
      • Topical therapy failure: The patient did NOT respond to topical therapy.
      • Immunocompromised status: The patient is immunocompromised.

    Step Therapy

    StepQualifying pathwayPolicy requirement
    1Failure of topical therapyThe patient did not respond to topical therapy.
    1Alternative qualifying circumstanceThe patient has extensive disease, dermatophyte folliculitis, or is immunocompromised.

    Provider Actions and Authorization Risks

    Prior Authorization

    Onychomycosis Authorization Requirements

    Authorization may be granted for onychomycosis due to dermatophytes (tinea unguium) only when the diagnosis is confirmed by an appropriate fungal diagnostic test and the requested drug is not being used in a footbath.

    • Diagnosis is due to dermatophytes (tinea unguium).
    • All listed onychomycosis conditions must be met.
    Prior Authorization

    Tinea Capitis Authorization

    For tinea capitis, authorization may be granted only when the requested drug is not being used in a footbath.

    • Document the treatment indication as tinea capitis.
    • Confirm the requested drug is not being used in a footbath.

    Unsupported block type: prior_auth

    Documentation Required

    Topical Therapy Failure May Qualify

    Failure to respond to topical therapy is one qualifying circumstance for oral terbinafine treatment of tinea corporis or tinea cruris. Other qualifying circumstances may also support authorization.

    • Extensive disease.
    • Dermatophyte folliculitis is present.
    • The patient is immunocompromised.
    Documentation Required

    Fungal Diagnostic Confirmation Required

    For onychomycosis, document an appropriate fungal diagnostic test confirming the diagnosis before requesting authorization.

    • Examples include potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy.
    Denial Risk

    Onychomycosis Criteria Not Met

    Onychomycosis authorization criteria are not met when the diagnosis lacks fungal diagnostic confirmation or when the requested drug is being used in a footbath.

    • Absent or inadequate confirmation by KOH preparation, fungal culture, nail biopsy, or another appropriate fungal diagnostic test.
    • Requested drug is being used in a footbath.
    Denial Risk

    Compendial-Use Criteria Not Met

    Compendial-use criteria are not met when the requested drug is being used in a footbath. For tinea corporis or tinea cruris, authorization is also not supported without at least one qualifying circumstance.

    • Tinea corporis or tinea cruris must involve extensive disease, dermatophyte folliculitis, failure to respond to topical therapy, or immunocompromised status.
    • The requested drug must not be used in a footbath.

    Clinical Background

    Terbinafine tablets are indicated for onychomycosis of the toenail or fingernail caused by dermatophytes. Recognized compendial uses include tinea capitis and selected cases of tinea corporis or tinea cruris, subject to the policy’s qualifying clinical criteria.

    Condition Definitions

    Onychomycosis (tinea unguium)
    DefinitionFungal infection of a toenail or fingernail caused by dermatophytes.
    Tinea capitis
    DefinitionDermatophyte infection of the scalp.
    Tinea corporis and tinea cruris
    DefinitionDermatophyte infection of the body or groin, respectively.
    Coverage limitationCoverage is limited to cases with extensive disease, dermatophyte folliculitis, failure to respond to topical therapy, or immunocompromised status.
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization Terbinafine Tablets
    Policy CodePolicy 364-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionFor onychomycosis, document confirmation of the diagnosis with a fungal diagnostic test and confirm that terbinafine is not being used in a footbath.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaStep TherapyProvider Actions and Authorization RisksClinical BackgroundCondition Definitions
    Administration restriction: The requested drug is NOT being used in a footbath.